Discontinued — last reported Q3 '25
Net product sales — Remaining performance obligations
Moderna Net product sales — Remaining performance obligations decreased by 49.4% to $79.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 78.1%, from $361.00M to $79.00M. Over 2 years (FY 2022 to FY 2024), Net product sales — Remaining performance obligations shows a downward trend with a -67.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates a growing backlog of contracted revenue, which provides better visibility into future financial performance.
Detailed definition
This represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsat...
Peer comparison
Standard metric reported under ASC 606, comparable to 'backlog' or 'deferred revenue' in companies with long-term commercial contracts.
mrna_segment_net_product_sales_remaining_performance_obligationsHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.90B | $6.20B | $5.50B | $4.00B | $3.90B | $2.00B | $1.20B | $1.00B | $1.40B | $554.00M | $522.00M | $645.00M | $361.00M | $130.00M | $96.00M | $156.00M | $79.00M |
| QoQ Change | — | -21.5% | -11.3% | -27.3% | -2.5% | -48.7% | -40.0% | -16.7% | +40.0% | -60.4% | -5.8% | +23.6% | -44.0% | -64.0% | -26.2% | +62.5% | -49.4% |
| YoY Change | — | — | — | — | -50.6% | -67.7% | -78.2% | -75.0% | -64.1% | -72.3% | -56.5% | -35.5% | -74.2% | -76.5% | -81.6% | -75.8% | -78.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Moderna's net product sales — remaining performance obligations?
- Moderna (MRNA) reported net product sales — remaining performance obligations of $79.00M in Q3 2025.
- How has Moderna's net product sales — remaining performance obligations changed year-over-year?
- Moderna's net product sales — remaining performance obligations decreased by 78.1% year-over-year, from $361.00M to $79.00M.
- What is the long-term trend for Moderna's net product sales — remaining performance obligations?
- Over 2 years (2022 to 2024), Moderna's net product sales — remaining performance obligations has grown at a -67.2% compound annual growth rate (CAGR), from $15.40B to $1.66B.
- What does net product sales — remaining performance obligations mean?
- The value of future sales that are already under contract but have not yet been delivered or recognized as revenue.